Impact of edoxaban approval for venous thromboembolism on length of hospitalization
, 2017 Keishi Suzuki +9 more
openalex +2 more sources
Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal [PDF]
, 2016 core +1 more source
DEN OpenObjectives There are limited reports on the safety of gastrointestinal endoscopic procedures in individuals taking edoxaban, one of the direct oral anticoagulants.
Ken‐ichi Mizuno +9 more
doaj +1 more source
193 Edoxaban versus warfarin on stroke risk in patients with atrial fibrillation: a territory-wide cohort study [PDF]
, 2021 Che Him Dicken Kong +10 more
openalex +1 more source
Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism [PDF]
, 2017 Direct oral anticoagulants (DOACs) specifically target factor IIa or Xa and represent a major step forward in the treatment of acute- and long-term prevention of venous thrombo-embolism (VTE).
Bounameaux, Henri +2 more
core
Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review
, 2015 Adam Cuker, Holleh Husseinzadeh
openalex +2 more sources
New Oral Anticoagulants for the Treatment of Venous Thromboembolism: Understanding Differences and Similarities [PDF]
, 2014 core +1 more source
Comparative risk impact of edoxaban in the management of stroke and venous thromboembolism
Therapeutics and Clinical Risk Management, 2016 Katie B Tellor, Joseph S Van Tuyl, Anastasia L Armbruster Department of Pharmacy Practice, St Louis College of Pharmacy, St Louis, MO, USA Abstract: Edoxaban, a factor Xa inhibitor, was approved by the United States Food and Drug Administration in
Tellor KB, Van Tuyl JS, Armbruster AL
doaj
Edoxaban monitoring strategy using chromogenic anti-Xa assays among patients with atrial fibrillation [PDF]
Anna Gavrilova +5 more
openalex +1 more source